ELAVL3 stabilizes MYCN mRNA and provides a therapeutic target in neuroendocrine prostate cancer [LNCaP/AR/shTP53/shRB1]
Ontology highlight
ABSTRACT: Here we demonstrated that the RNA-binding protein ELAVL3 is specifically upregulated in NEPC, and that overexpression of ELAVL3 alone sufficiently induce neuroendocrine phenotype in prostate adenocarcinoma. Pharmacological inhibition of ELAVL3 with pyrvinium pamoate, an FDA-approved drug, effectively suppressed tumor growth, reduced the risk of metastases, and improved the survival of NEPC mice models.
ORGANISM(S): Homo sapiens
PROVIDER: GSE224909 | GEO | 2023/10/23
REPOSITORIES: GEO
ACCESS DATA
